KA (kinetabio.com) Enterprise Value-to-Revenue Coefficient

kinetabio.com (KA) - corporate logo

The development of immunotherapy at Kineta, Inc. (KA) relies on a medical innovation cycle that remains independent of macroeconomic trends. This enterprise value-to-revenue chart visualizes this dynamic, where the indicator expresses the current state of the capitalization valuation metric. Future revenues are based on the commercialization of drugs targeting solid tumors, while a unique scientific approach ensures the company secures high royalties from global pharma behemoths.

Kineta - KA EV/Sales Multiple (period 07/04/2022 - 11/20/2026)

Kineta Inc - analytical breakdowns and key metrics (KA)

- stock value and consensus price forecast:
- business market valuation indicators:
Initial company analysis:Kineta
Product sample of Kineta

Kineta, Inc. (KA) possesses significant pricing power in the immuno-oncology segment due to the uniqueness of the KVA12.1 antibody, rendering the company's revenue a strategic asset. The current EV/Sales multiple of reflects the total enterprise value excluding debt, allowing investors to assess whether the stock is overvalued relative to actual sales and determine if the price constitutes a value trap.

Direct competitors

IBRX (immunitybio.com) - Company Value to Revenue Ratio|Immunocore Corp (IMCR) - Enterprise Value-to-Revenue Ratio|Enterprise Value-to-Revenue Multiple Janux Pharma (JANX)|Company Value to Revenue RCUS|ZYME - Enterprise Value-to-Sales Ratio|Company Value to Revenue TNGX (Tango Pharma)|Enterprise Value-to-Revenue Coefficient IOVA|EV/Sales Multiple IMTX (Immatics)|Business Value to Revenue XNCR|compasstherapeutics.com - EV/Sales Multiple|Enterprise Value-to-Revenue Multiple Replimune Inc.|Lyell Immunopharma (LYEL) - Enterprise Value-to-Revenue Ratio|Innate Pharma S.A. - Business Value to Revenue|PYXS (Pyxis) - EV/Sales Multiple|EV/Sales Multiple cgen.com|Enterprise Value-to-Revenue Ratio IO Biotech (IOBT)|STRO: Enterprise Value to Sales Volume|MiNK Therapeutics Inc. - Company Value to Revenue|werewolftx.com (HOWL) - Enterprise Value-to-Revenue Multiple|Immix Biopharma Inc. - EV/Sales Multiple|ALXO - EV/Sales Multiple|CUE: EV/Sales Multiple|Company Value to Revenue Ratio PDSB|Enterprise Value-to-Revenue Ratio Sonnet BioTherapeutics Holdings|MAIA Biotechnology (MAIA) - Total Company Value-to-Revenue Ratio|EV/Sales Multiple LIMN|EV/Sales Multiple Lava Tx (LVTX)|EV/Sales Multiple NXTC (NextCure Corporation)|Business Value to Revenue LPTX|INTS - Enterprise Value-to-Revenue Ratio|Total Company Value-to-Revenue Ratio Sensei Biotherapeutics Inc SNSE|TOVX: EV/Sales Multiple|Enterprise Value-to-Revenue Multiple Gritstone Bio (GRTS)|Enterprise Value-to-Revenue Ratio NexImmune, Inc.|Company Value to Revenue Ratio TSBX (Turnstone Biologics)|Company Value to Revenue VCNX (Vaccinex, Inc.)|Enterprise Value-to-Revenue Coefficient HARP